Zoetis Securities Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Source: Globenewswire
- Class Action Initiated: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Declining Market Share: The lawsuit claims that veterinarian prescription growth and adoption of Zoetis' flagship product Librela have sharply weakened due to FDA safety warnings regarding serious neurological complications in dogs, leading to significant investor losses.
- Increased Competitive Pressure: Zoetis' Simparica Trio is losing substantial market share to a lower-priced competing canine parasiticide with broader indicated use, reflecting a slowdown in the overall market that further impacts the company's performance.
- Product Market Challenges: Zoetis' dermatology products, Apoquel and Cytopoint, are also facing significant market share losses due to newly launched competing treatments, indicating a weakening competitive position in its core product lines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 72.450
Low
130.00
Averages
154.20
High
200.00
Current: 72.450
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, that they must apply to be lead plaintiff by July 27, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Zoetis made false and misleading statements during the class period, claiming strong market share and sales growth for its flagship products, while in reality, veterinarian prescription growth and adoption rates sharply weakened, leading to investor losses.
- Competitive Market Pressure: Zoetis' Simparica Trio is losing significant market share to a lower-priced competing product with broader indications, reflecting a slowdown in the overall market and increasing competition.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating extensive experience and a successful track record, urging investors to carefully select qualified legal counsel to protect their interests.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Zoetis Inc., covering investors who purchased securities between January 14, 2025, and May 6, 2026, alleging significant misstatements and omissions regarding product adoption that could lead to investor losses.
- Key Allegations: The lawsuit claims that Zoetis failed to disclose weakening market performance of its products, particularly Librela, which saw reduced usage following FDA safety warnings, and Simparica Trio, which lost market share to cheaper competitors, impacting the company's overall market position and future outlook.
- Stock Price Impact: On May 7, 2026, Zoetis reported a significant decline in its Companion Animal business, resulting in a 21.5% drop in stock price, reflecting investor concerns about the company's future profitability and operational stability.
- Investor Action: Affected investors must file for lead plaintiff status by July 27, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations to ensure the protection of investors' legal rights.
See More
Michael Burry Shorting Micron Amid AI Hype
- Micron Valuation Concerns: Michael Burry highlights that Micron's stock has reached historically extreme levels, having experienced 34 drawdowns of over 30% in the past 42 years, indicating poor long-term profitability with a median return on invested capital of only 4%.
- AI Hype-Driven Market Sentiment: Burry argues that Micron's recent rally is primarily fueled by investor FOMO and the greater fool theory rather than rational analysis, suggesting a lack of confidence in the company's fundamentals.
- Short and Long Position Strategy: While shorting Micron, Burry has increased his stakes in PayPal, Sprouts Farmers Market, Zoetis, Fannie Mae, and Freddie Mac, reflecting his optimistic outlook on these companies' long-term prospects.
- Retail Sentiment and Market Reaction: Despite Burry's bearish stance on Micron, retail sentiment remains bullish, with message volume surging by 260% over the past 90 days, indicating sustained market interest in the stock.
See More
Zoetis Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis, seeking damages for investors who purchased securities between January 14, 2025, and May 6, 2026, highlighting significant investor concerns regarding the company's transparency and compliance.
- False Statements Allegations: The complaint alleges that Zoetis made materially false and misleading statements regarding market share and veterinarian adoption of key products, particularly as sales growth for Librela and Simparica Trio weakened due to FDA safety warnings, undermining investor confidence.
- Market Share Loss: Zoetis' Simparica Trio is losing significant market share to lower-priced competitors, which, in the context of a slowing overall market, could further impact the company's financial performance and strategic positioning.
- Investor Action Window: Affected investors have until July 27, 2026, to request lead plaintiff status, indicating that the legal risks faced by the company may affect its stock price and market confidence, necessitating close monitoring of developments.
See More
Zoetis Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Zoetis, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by July 27, 2026, indicating significant legal risks that could impact the company's reputation.
- Disappointing Earnings: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year earnings guidance to between $6.85 and $7.00 per share from a previous range of $7.00 to $7.10, reflecting operational challenges and softening market demand.
- Stock Price Plunge: Following the earnings report, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31, highlighting investor concerns regarding the company's future profitability and potentially leading to further declines in market confidence.
- Changing Market Dynamics: CEO Kristin Peck noted increased price sensitivity among pet owners, resulting in fewer veterinary visits and weaker demand, indicating that the company faces escalating challenges in the current economic environment, which may affect its long-term growth prospects.
See More
Class Action Lawsuit Filed Against Zoetis Inc. for Securities Violations
- Class Action Reminder: The Schall Law Firm has alerted investors about a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from January 14, 2025, to May 6, 2026, with a deadline for participation set for July 27, 2026.
- False Statements Allegation: The complaint alleges that Zoetis made false and misleading statements during the class period, resulting in investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Market Share Decline: Zoetis's Trio product has lost market share to competitors, while its dermatology products Apoquel and Cytopoint have also been adversely affected by the introduction of new competing treatments, intensifying the company's market challenges.
- Investor Losses: As the market became aware of Zoetis's actual situation, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting significant deficiencies in the company's transparency and compliance.
See More
Zoetis Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, that they must apply to be lead plaintiff by July 27, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Zoetis made false and misleading statements during the class period, claiming strong market share and sales growth for its flagship products, while in reality, veterinarian prescription growth and adoption rates sharply weakened, leading to investor losses.
- Competitive Market Pressure: Zoetis' Simparica Trio is losing significant market share to a lower-priced competing product with broader indications, reflecting a slowdown in the overall market and increasing competition.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating extensive experience and a successful track record, urging investors to carefully select qualified legal counsel to protect their interests.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Zoetis Inc., covering investors who purchased securities between January 14, 2025, and May 6, 2026, alleging significant misstatements and omissions regarding product adoption that could lead to investor losses.
- Key Allegations: The lawsuit claims that Zoetis failed to disclose weakening market performance of its products, particularly Librela, which saw reduced usage following FDA safety warnings, and Simparica Trio, which lost market share to cheaper competitors, impacting the company's overall market position and future outlook.
- Stock Price Impact: On May 7, 2026, Zoetis reported a significant decline in its Companion Animal business, resulting in a 21.5% drop in stock price, reflecting investor concerns about the company's future profitability and operational stability.
- Investor Action: Affected investors must file for lead plaintiff status by July 27, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations to ensure the protection of investors' legal rights.
See More
Michael Burry Shorting Micron Amid AI Hype
- Micron Valuation Concerns: Michael Burry highlights that Micron's stock has reached historically extreme levels, having experienced 34 drawdowns of over 30% in the past 42 years, indicating poor long-term profitability with a median return on invested capital of only 4%.
- AI Hype-Driven Market Sentiment: Burry argues that Micron's recent rally is primarily fueled by investor FOMO and the greater fool theory rather than rational analysis, suggesting a lack of confidence in the company's fundamentals.
- Short and Long Position Strategy: While shorting Micron, Burry has increased his stakes in PayPal, Sprouts Farmers Market, Zoetis, Fannie Mae, and Freddie Mac, reflecting his optimistic outlook on these companies' long-term prospects.
- Retail Sentiment and Market Reaction: Despite Burry's bearish stance on Micron, retail sentiment remains bullish, with message volume surging by 260% over the past 90 days, indicating sustained market interest in the stock.
See More
Zoetis Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Zoetis, seeking damages for investors who purchased securities between January 14, 2025, and May 6, 2026, highlighting significant investor concerns regarding the company's transparency and compliance.
- False Statements Allegations: The complaint alleges that Zoetis made materially false and misleading statements regarding market share and veterinarian adoption of key products, particularly as sales growth for Librela and Simparica Trio weakened due to FDA safety warnings, undermining investor confidence.
- Market Share Loss: Zoetis' Simparica Trio is losing significant market share to lower-priced competitors, which, in the context of a slowing overall market, could further impact the company's financial performance and strategic positioning.
- Investor Action Window: Affected investors have until July 27, 2026, to request lead plaintiff status, indicating that the legal risks faced by the company may affect its stock price and market confidence, necessitating close monitoring of developments.
See More
Zoetis Faces Class Action Lawsuit Amid Stock Plunge
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Zoetis, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by July 27, 2026, indicating significant legal risks that could impact the company's reputation.
- Disappointing Earnings: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year earnings guidance to between $6.85 and $7.00 per share from a previous range of $7.00 to $7.10, reflecting operational challenges and softening market demand.
- Stock Price Plunge: Following the earnings report, Zoetis's stock price fell by $23.91, or 21.5%, closing at $87.31, highlighting investor concerns regarding the company's future profitability and potentially leading to further declines in market confidence.
- Changing Market Dynamics: CEO Kristin Peck noted increased price sensitivity among pet owners, resulting in fewer veterinary visits and weaker demand, indicating that the company faces escalating challenges in the current economic environment, which may affect its long-term growth prospects.
See More
Class Action Lawsuit Filed Against Zoetis Inc. for Securities Violations
- Class Action Reminder: The Schall Law Firm has alerted investors about a class action lawsuit against Zoetis for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from January 14, 2025, to May 6, 2026, with a deadline for participation set for July 27, 2026.
- False Statements Allegation: The complaint alleges that Zoetis made false and misleading statements during the class period, resulting in investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth due to FDA safety warnings.
- Market Share Decline: Zoetis's Trio product has lost market share to competitors, while its dermatology products Apoquel and Cytopoint have also been adversely affected by the introduction of new competing treatments, intensifying the company's market challenges.
- Investor Losses: As the market became aware of Zoetis's actual situation, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting significant deficiencies in the company's transparency and compliance.
See More
